Suzhou Connect Biopharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Taicang China (2012)
Status: Defunct (2021)

Organization Overview

First Clinical Trial
2014
NCT02280434
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Connect Biopharma Australia Pty Ltd | Suzhou Connect Biopharmaceuticals, Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

cbp-201 (7 trials)

Drugs in Phase 2 Trials (1)

cbp-307 (4 trials)

Drugs in Phase 1 Trials (2)

cbp-174 (1 trial)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autoimmune Diseases (Phase 1)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 4